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Abstract 
Azoreductases are flavoenzymes that have been characterised in a range of prokaryotes and 
eukaryotes. Bacterial azoreductases are associated with the activation of two classes of drug, azo 
drugs for the treatment of inflammatory bowel disease and nitrofuran antibiotics. The mechanism of 
reduction of azo compounds is presented that requires tautomerisation of the azo compound to a 
quinoneimine and provides a unifying mechanism for the reduction of azo and quinone substrates 
by azoreductase. The importance of further work in characterisation of azoreductases from enteric 
bacteria is highlighted to aid in the development of novel drugs for the treatment of colon related 
disorders.    
Human azoreductases are known to play a crucial role in the metabolism of a number of quinone 
containing cancer chemotherapeutic drugs. The mechanism of hydride transfer to quinones, which is 
shared not only between eukaryotic and prokaryotic azoreductases but the wider family of NAD(P)H 
quinone oxidoreductases, is outlined. The importance of common SNPs in human azoreductases is 
described not only in cancer prognosis but also due to their effects on the efficacy of quinone drug 
based cancer chemotherapeutic regimens. This highlights the need to screen patients for 
azoreductase SNPs ahead of treatment with these regimens.  
 
   
 
 
 
 
 
 
Non-approved abbreviations 
5-ASA: 5-aminosalicylate, AcpD: acyl carrier protein phosphodiesterase, ecAzoR: E. coli azoreductase, 
FAD: flavin adenine dinucleotide, FMN: Flavin mononucleotide, hNQO1/2: human NAD(P)H quinone 
oxidoreductase 1 and 2, IBD: inflammatory bowel disease, MdaB: Modulator of drug activity B, 
NAD(P)H: Nicotinamide adenine dinucleotide (phosphate) reduced, NfsB: Nitrofurazone sensitivity 
protein B, NRH:(Wu et al., 1997) dihydronicotinamide riboside, paAzoR: P. aeruginosa azoreductase, 
ppAzoR: Pseudomonas putida azoreductase, WrbA: Tryptophan repressor binding protein A 
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Introduction to azoreductases 
Azoreductases are a group of diverse enzymes found in many bacterial and eukaryotic organisms (Fig 
1 (Ryan et al., 2014)). The azoreductases discussed in this review are flavin-dependent (typically 
FMN) enzymes that are able to reductively cleave compounds containing an azo bond. Azo 
compounds are defined as those that contain an R1-N=N-R2 group, where R1 and R2 are typically 
aromatic groups. Azoreductases are primarily cytosolic enzymes, however they have been shown to 
be secreted during exposure of bacteria to azo dyes (Morrison et al., 2015). The physiological role of 
these enzymes in the bacteria remains unclear, however they are constitutively expressed during 
growth in vitro (Chen et al., 2005; Wang et al., 2007) which suggests a role in homeostasis.  The 
majority of azoreductase research is focused on their use in bioremediation where they can be used 
for the treatment of waste water contaminated with azo dyes from the textile and cosmetics 
industries (Singh et al., 2015). This review is unique in focusing on their role in the activation of 
several classes of drug.   
To date the majority of studies on azoreductases have been performed on enzymes from aerobic 
bacteria (Crescente et al., 2016; Nakanishi et al., 2001), in contrast only a single azoreductase has 
been characterised from a strict anaerobe (Morrison et al., 2012). Several species of gut bacteria 
have been identified to have azoreductase activities (Wang et al., 2004) however studies on 
individual azoreductases from enteric bacteria are very limited. Due to the anaerobic environment of 
the gut it will be important to improve our understanding of the azoreductases which predominate 
in these bacteria in order to help design novel drugs.  
Reduction of substrates by azoreductases requires the use of either NADH or NADPH as an electron 
donor in a bi-bi ping pong mechanism (Binter et al., 2009; Nakanishi et al., 2001; Wang et al., 2010). 
Reduction is an obligate two electron process where a hydride is transferred from NAD(P)H to FMN 
and then on to the second substrate. Reduction of an azo substrate requires two NAD(P)H per azo 
substrate (Fig 2A). As well as azo compounds, the enzymes have been shown to reduce a range of 
other substrates including quinones (Gonçalves et al., 2013; Ryan et al., 2014; Ryan et al., 2010b) 
and nitroaromatics (Liu et al., 2007a; Prosser et al., 2013; Ryan et al., 2011). The physiological 
substrate of azoreductases remains unclear, however the high specific activity of azoreductases 
when reducing quinones (Ryan et al., 2014) and increased survival of E. coli overexpressing AzoR 
during treatment with menadione (Liu et al., 2008), suggest that detoxification of quinones is an 
important physiological function.  
The structures of several bacterial azoreductases have been solved and all share a characteristic 
homodimeric short-flavodoxin fold (Fig 2B). The active sites of these enzymes are situated at the 
dimer interface and are formed by residues from both monomers (Fig 2C). One molecule of flavin is 
bound within each active site and is required for activity. The structure of Escherichia coli 
azoreductase (ecAzoR) depicted in Figure 2 was the first to be solved (Ito et al., 2006) and is typical 
of those whose structures were subsequently solved (figure 3 for examples (Binter et al., 2009; 
Gonçalves et al., 2013; Liu et al., 2007b; Wang et al., 2007; Yu et al., 2014)). Azoreductases can be 
encoded by a diverse range of sequences (Fig 1 (Ryan et al., 2014)) as a result there are very few 
conserved residues in the protein and the ones that are present are thought to provide structural 
stability (Ryan et al., 2010a). The substrate binding pocket is typically lined by hydrophobic and 
aromatic residues (Fig 2C). Several of these aromatic residues are part of the β-hairpin that forms 
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the “lid” of the active site and these have been shown, via mutagenesis, to play an important role in 
determining the substrate specificity of the enzyme (Wang et al., 2010). The FMN is anchored by a 
series of sequence independent hydrogen bonds to a structural motif referred to as the FMN binding 
cradle (Ryan et al., 2010a) which is conserved in both bacterial and eukaryotic azoreductases.  
The structures of several azoreductases with bound substrates have been solved and these include 
with azo compounds (Fig 3 (Gonçalves et al., 2013; Ryan et al., 2010a; Wang et al., 2007; Wang et al., 
2010; Yu et al., 2014)), nitroaromatics (Ryan et al., 2011) and quinones (Gonçalves et al., 2013; Ryan 
et al., 2014). These substrates all lie sandwiched between the isoalloxazine rings of the flavin, with 
which they form π-π stacking interactions, and the aromatic residues of the β-hairpin (Fig 3). In 
general the substrates of azoreductases do not make many specific hydrophilic interactions 
explaining the ability of the active site to accommodate a range of hydrophobic substrates. So far no 
structure has been solved with a nicotinamide cofactor bound to an azoreductase. The structure of 
azoreductase with bound cibacron blue, a competitive NAD(P)H inhibitor, has been solved (Yu et al., 
2014) but this does not give details of binding due to the structural differences between it and 
NAD(P)H.   
Phylogeny of azoreductases 
Defining which enzymes have azoreductase activity is a complex matter. In 2014 a phylogenetic tree 
was published that brought together all of the characterised flavin-dependent azoreductases and a 
number of related NAD(P)H quinone oxidoreductases (adapted in Fig. 1 (Ryan et al., 2014)). Using 
this tree three distinct classes of characterised azoreductases can be defined. Class 1 is the most 
widespread and studied class of bacterial azoreductases. These enzymes have, since the sequencing 
of the first bacterial genomes been misidentified as acyl carrier protein phosphodiesterases (AcpD). 
Although several of these enzymes have been tested none have been shown to have AcpD activity 
(Nakanishi et al., 2001; Wang et al., 2007). In figure 1, class 1 azoreductases include P. aeruginosa 
azoreductases 1-3 (paAzoR1-3 (Ryan et al., 2010a; Wang et al., 2007)), Enterococcus faecalis 
azoreductase (Chen et al., 2004) and ecAzoR (Nakanishi et al., 2001). All members of this class share 
at least 30-40% sequence identity and are readily identifiable in most bacterial genomes. Class 2 
bacterial azoreductases are much less common in bacterial genom s and share no significant 
sequence identity with class 1 enzymes. Class 2 enzymes do however share the same enzymatic 
activities and overall fold  as enzymes from class 1 (Binter et al., 2009). In figure 1, class 2 are 
represented by azoreductases from Bacillus subtilis (Binter et al., 2009) and Rhodobacter 
sphaeroides (Bin et al., 2004). Class 3 enzymes are the mammalian azoreductases including hNQO1 
and hNQO2 that will be discussed in subsequent sections.  
The reason for inclusion of the NAD(P)H quinone oxidoreductases in figure 1 was that a novel 
mechanism for azoreduction was proposed (see below (Ryan et al., 2010a)) which suggested that the 
quinone and azo reduction shared the same mechanism in these enzymes (Ryan et al., 2010b). To 
support this enzymes were identified in P. aeruginosa from four families (ArsH, modulator of drug 
activity B, WrbA and YieF) which are characterised NAD(P)H quinone oxidoreductases in other 
bacteria (Ryan et al., 2014). The enzymes identified in P. aeruginosa were cloned expressed and 
characterised and all except WrbA (the most distantly related homologue) showed azoreductase 
activity (Crescente et al., 2016). This indicates that the azoreductase family is larger than originally 
thought and more work is needed to characterise further members.  
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Azo drugs 
The use of azo compounds as drugs stretches back to the first commercially available antibiotic, 
prontosil (Sup Fig 1) a sulphonamide prodrug, which was identified in the 1930s (Colebrook et al., 
1936) and was later used to identify the first azoreductase (Fouts et al., 1957). Prontosil was among 
the first drugs to be used to illustrate the importance of the mammalian gut microflora in drug 
metabolism (Gingell et al., 1971). In modern clinics azo drugs, such as olsalazine, are used to treat 
inflammatory bowel disease (IBD) and ulcerative colitis (Lautenschlager et al., 2014). Azo drugs for 
the treatment of IBD are pro-drugs that release the non-steroidal anti-inflammatory 5-
aminosalicylate (5-ASA (Makins et al., 2001)) upon reduction. In these prodrugs 5-ASA (Sup Fig 1) is 
covalently linked via an azo bond to an inert carrier to prevent rapid adsorption from the digestive 
tract (Haagen Nielsen et al., 1983). These drugs rely upon cleavage of the azo bond by azoreductases 
secreted by the gut microflora in order to release 5-ASA (Peppercorn et al., 1972).  
The use of azo-linked compounds for specific drug delivery to the gut remains an area of great 
interest. As well as anti-inflammatory compounds a range of other drugs are being targeted using 
azo chemistry and they include antibiotics (Deka et al., 2015; Kennedy et al., 2011) and anticancer 
drugs (Plyduang et al., 2014; Sharma et al., 2013). Development continues on new azo bonded 
carriers for drugs (Kim et al., 2016; Ruiz et al., 2011b) as well as linking pairs of drugs together (Ruiz 
et al., 2011a). Studies are making use of the azo linkage in new systems such as using azo polymers 
as a coating material which is degraded to release the drug (Saphier et al., 2010). Other studies 
investigate the use azo linked nanoparticles to release drugs into the colon (Naeem et al., 2014) or 
azo containing hydrogels to release olsalazine upon reduction (Li et al., 2010). 
The mechanism of azoreduction 
The basic mechanism for azoreduction by all FMN dependent azoreductases is described in figure 
2A. In this mechanism N5 of FMN accepts a hydride during oxidation of NAD(P)H and donates it 
upon reduction of substrate (Fig 4). The structures of three azoreductases with azo substrates bound 
have been solved (Fig 3) and in each the azo bond is not in an optimal position for hydride transfer 
(distance from N5 of FMN varies 4.8-6.3 Å, transfer distance should be ~3.5 Å). There is unlikely to 
be a significant shift in position of the substrate as a result of FMN reduction as comparison of 
ecAzoR in the oxidised and reduced states showed little conformational change to the residues 
surrounding the active site (Ito et al., 2008). This makes direct transfer of the hydride to the 
substrate azo bond unlikely and leaves the question of what is the site of electron transfer.     
The answer was provided when the structure of balsalazide bound to paAzoR1 was solved (Fig. 3A 
(Ryan et al., 2010a)). The clue was that although balsalazide should be planar due to its conjugated 
system the electron density clearly indicated a 50° bend in the molecule at the azo bond. In order to 
account for this anomaly an alternative explanation was put forward in which the azo compound 
was in fact in the hydrazo tautomer (Fig. 3B). Tautomerisation introduces an sp3 hybridized nitrogen 
into the azo bond which would account for the bend in the electron density. Tautomerisation also 
means the salicylate ring forms a quinoneimine structure that is in a more optimal position to be 
reduced and would account for the ability of these enzymes to reduce both quinones and azo 
compounds (Ryan et al., 2014). As a result a novel mechanism of azoreduction was proposed based 
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upon reduction of the quinoneimine containing tautomer (Fig. 4). In this mechanism the hydride is 
transferred to the carbon at position 2 of quinonimine ring of balsalazide as the covalently bonded 
carboxylate would make the carbon δ+.    
Subsequently two structures of azoreductases complexed with their azo substrates (Fig. 3C and 3D) 
have been published (Gonçalves et al., 2013; Yu et al., 2014) which show the azo compounds in a 
more planar conformation. Both azo drugs should be able to tautomerise to form a hydrazo 
tautomer. In both structures a carbon atom from the quinoneimine ring formed via tautomerisation 
of the azo substrate is in a similar position to carbon 2 of balsalazide and in an optimal distance for 
hydride transfer (3.4 Å and 3.7 Å) consistent with the mechanism in figure 4. 
Nitrofuran and other nitroaromatic drug activation by azoreductases 
The number of drugs that incorporate a nitroaromatic group is relatively small due to their toxicity 
which stems from their ability to generate ROS via redox cycling via single electron reduction. Four 
electron reduction of the nitro-group generates a reactive hydroxylamine which can covalently 
modify either proteins or DNA (Kovacic et al., 2014). Among the most heavily studied nitroaromtic 
azoreductase substrates are the nitrofuran antibiotics. The most commonly studied nitrofurans are, 
nitrofurazone which is a topical antibiotic for treating burns (Ungureanu, 2014), and nitrofurantoin  
(Sup Fig 1) used for treating urinary tract infections (Garau, 2008). Although typically used as 
antibiotics nitrofurans are also able to kill trypanosomatids (Patterson et al., 2014).  
All nitrofurans must be activated via reduction of their nitro group to a reactive hydroxylamine 
(Whiteway et al., 1998). In bacteria this can be achieved either via dedicated nitroreductases such as 
NfsB in E. coli (Race et al., 2005) or azoreductases (Ryan et al., 2011). The structure of paAzoR1 was 
solved in complex with nitrofurazone (Fig 5A (Ryan et al., 2011)). The nitro group of nitrofurazone is 
positioned over the N5 of FMN to allow optimal hydride transfer (3.6 Å – Fig. 5B and C). The nitro 
group is within hydrogen bonding range (3 Å) of the side chain of Asn99 which would stabilise the 
reduced form and also a water molecule which could donate a proton required for reduction.   
Mammalian azoreductases  
Like bacteria, eukarya including mammals have azoreductases. In humans the azoreductases are 
referred to as NAD(P)H quinone oxidoreductase 1 and 2 (hNQO1 and hNQO2 (Wu et al., 1997)). 
Although they share limited sequence identity (<10%) to either class 1 or 2 azoreductases they are 
able to reduce many of the same classes of substrates via the same bi-bi ping pong mechanism (Wu 
et al., 1997). Similarly to bacterial azoreductases, hNQO1 and hNQO2 have flavodoxin-like folds and 
form homodimers in solution (Fig 6A (Faig et al., 2000)). Both hNQO1 and hNQO2 use FAD as a 
cofactor rather than FMN (Fig 6B). hNQO1, is an important phase II drug metabolising enzyme that is 
expressed in many tissues throughout the body (Siegel et al., 2000). hNQO1 is overexpressed in 
many cancers including, lung (Li et al., 2015), breast (Yang et al., 2014) and pancreatic tumours 
(Lewis et al., 2005). hNQO1 is known to control degradation of a range of proteins by the 
proteasome including the tumour suppressors p53 (Asher et al., 2001) and p73 (Asher et al., 2005) 
which is likely to contribute to its role in tumorigenesis. There is also an association between the 
common (allelic frequency 0.22 in Caucasians and 0.45 in Asian populations (Kelsey et al., 1997)) 
C609T NQO1 SNP (P187S mutant) and cancer (Fagerholm et al., 2008; Lajin et al., 2013). The P187S 
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mutation results in a reduced affinity of hNQO1 for FAD and thus reduced enzymic activity and an 
increased susceptibility to proteolysis (Lienhart et al., 2014).  
The role of hNQO2 in cells is less clear than for hNQO1. hNQO2 expression is less widespread than 
hNQO1 and is mainly found in muscle and kidney (Jaiswal, 1994). hNQO2 is unusual in that it utilises 
both NADH and NADPH instead using dihydronicotinamide riboside (NRH (Wu et al., 1997)). Like 
hNQO1, hNQO2 is involved with the regulation of proteasomal degradation of some proteins such as 
cyclin D1 (Hsieh et al., 2012). hNQO2 has a common SNP (C659T or L47F) that does not affect 
enzymic activity but makes hNQO2 more susceptible to proteolysis (Megarity et al., 2014). hNQO2 
SNPs have been linked to prostate cancer (Mandal et al., 2012), colorectal cancer (Chen et al., 2016) 
and prognosis in breast cancer (Hubackova et al., 2012). hNQO2 has been associated with the 
activation of chemotherapeutics (Celli et al., 2006; Jamieson et al., 2011) and hNQO2 SNPs are 
associated with the cardiotoxicity of the anthraquinone idarubicin (Megias et al., 2015). Both 
imatinib (Ki ~40 nM (Bantscheff et al., 2007)) and chloroquine (Ki = 0.6 µM (Kwiek et al., 2004)) are 
known inhibitors of NQO2 and hNQO2 is likely to be a secondary target for both drugs in the cell. 
Mammalian azoreductases and chemotherapeutic drugs 
Azoreductases in bacteria have been shown to have 10-100 fold greater activity against quinones 
than against azo substrates (Crescente et al., 2016; Ryan et al., 2014). Quinones are highly cytotoxic 
due to their ability to undergo redox cycling via one or two electron reduction, but can also cause 
alkylation of cellular protein and DNA (Bolton et al., 2000). As a result quinones are not used as 
antibiotics however several quinones are either in use as cancer chemotherapeutics e.g. 
anthracyclines (Hortobagyi, 1997), or in clinical trials e.g. β-lapachone (currently in phase I/II trials 
for a range of cancers (Li et al., 2014)). Quinones such as Atovaquone are also used for the 
treatment of malaria (Looareesuwan et al., 1996). Metabolites of several drugs, including etoposide 
(Smith et al., 2014), famitinib (Xie et al., 2013) and troglitazone (Yamamoto et al., 2002) have been 
identified as having either quinone or related quinoneimine functional groups that  have been linked 
to their hepatotoxicity. As a result it is important to understand the role of human azoreductases in 
the cytotoxicity of quinone drugs.  
The cytotoxicity of a range of quinone based cancer chemotherapeutics are altered by hNQO1 
activity (Table 1). Many of these drugs are cytotoxic as they undergo redox cycling via reduction by 
NQO1 to their quinol form before oxidation back to the quinone and release of ROS (Docampo et al., 
1979). In contrast the reduction of tanespimycin to its quinol makes it a more potent inhibitor of its 
target Hsp90 (Guo et al., 2005). Although hNQO1 is primarily linked with the toxicity of quinone 
based chemotherapeutics it has been linked to some nucleoside analogues (Table 1). The reason for 
the change in resistance to nucleoside analogues is also thought be linked to their ability to generate 
ROS (Aresvik et al., 2010) and the antioxidant role played by hNQO1 (Bauer et al., 2012). As a result 
of the occurrence of both overexpression of hNQO1 and inactivating mutants of the enzyme as 
causative agents of cancer, this data would suggest that treatment of cancer with 
chemotherapeutics activated by hNQO1 is best undertaken after genotyping the patient. 
Alternatively fluorogenic substrates are under development that could circumvent the need for 
genotyping, significantly speeding up the process (Best et al., 2016; Silvers et al., 2013).  
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The mechanism of quinone reduction by hNQO1 and other azoreductases 
In order to better understand the mechanism of quinone reduction by flavoproteins the structures 
of a number of quinones have been solved bound to bacterial (Gonçalves et al., 2013; Ryan et al., 
2014) and mammalian azoreductases (Faig et al., 2000) as well as a recent structure E. coli 
tryptophan repressor binding protein A (WrbA (Degtjarik et al., 2016)). There are also structures of 
several quinones under development as chemotherapeutics complexed with hNQO1 (Faig et al., 
2001; Pidugu et al., 2016). EO9 or Apaziquone is a good example of an NQO1 substrate (Walton et 
al., 1991), it has entered phase 3 clinical trials for the treatment of bladder cancer (Phillips et al., 
2013). The structure of EO9 bound to hNQO1 is typical of other quinones bound to bacterial and 
mammalian azoreductases. In the structure of EO9 bound to hNQO1 the quinone oxygen is 3.6 Å 
from the N5 of FMN in an ideal location for electron transfer (Fig 6A). A quinone oxygen is similarly 
positioned in structures of paAzoR1 (3.7 Å (Ryan et al., 2014)) and ppAzoR (3.6 Å (Gonçalves et al., 
2013)) bound to anthraquinone-2-sulphonate. Transfer of the hydride to the carbonyl oxygen of the 
quinone as the mechanism of quinone reduction (Fig 6C) is supported by recent quantum 
mechanical calculations which were performed on a high resolution structure of WrbA bound to 
benzoquinone (Degtjarik et al., 2016).  
Mammalian azoreductases and nitroaromatic drugs 
As discussed above nitroaromatics are not commonly used in treatment due to their cytotoxic side 
effects however like quinones there are ongoing efforts to use them for the treatment of intractable 
diseases a good example of this is the prodrug CB1954 (Sup Fig 1). CB1954 has undergone clinical 
trials for the treatment of prostate cancer with virally encoded E. coli NfsB (Patel et al., 2009) and in 
a range of tumours with NRH (Middleton et al., 2010). As with nitrofurazone one or other of the 
nitro groups must be reduced to a hydroxylamine in order to activate the compound. hNQO2 
selectively reduces the 4’ nitro of CB1954 (Fig 5B (Fu et al., 2005)). Bacterial azoreductases also 
reduce the CB1954 (Liu et al., 2007a; Prosser et al., 2013) but at both nitro groups equally. The 
reason for the nitro-group selectivity in hNQO2 is believed to be Asn161 which orients the molecule 
within the active site (Fig. 5B (AbuKhader et al., 2005)). The 4’ nitro group of CB1954 is positioned in 
close contact with the N5 of FMN (3.5 Å) suggesting the mechanism of reduction is as described for 
nitrofurazone (Fig 5C).  
There is a lot of research targeting difficult to treat infections using nitroaromatic drugs. In neglected 
tropical diseases such as malaria (Cakmak et al., 2011) and sleeping sickness (Torreele et al., 2010) 
nitroaromatic compounds are selectively activated by parasite specific nitroreductases. BTZ043 is 
the first of a novel class of novel nitroaromatic drugs (Lechartier et al., 2012) that are showing 
promise for the treatment of extensively drug resistant Mycobacterium tuberculosis (Pasca et al., 
2010) and is now entering phase I clinical trials. As a result it is important to improve our 
understanding of nitroreduction by the human enzymes to avoid side effects resulting from host 
specific interactions with these novel classes of drugs.   
Conclusions 
Azoreductases are a diverse and adaptable protein family that play an important role in the 
metabolism of drugs by the gut microflora. In the area of bacterial azoreductases one of the key 
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challenges remains the characterisation of azoreductases encoded by bacteria found in the natural 
gut microflora in order to improve the design of novel azo prodrugs for the treatment of not only 
inflammatory bowel disease but other diseases of the colon. 
In recent years the importance of the human azoreductases in the area of cancer chemotherapy is 
coming to the fore. As increasing numbers of chemotherapy drugs rely on hNQO1 and hNQO2 for 
toxicity the need to genotype patients for the presence of inactivating mutations must now be 
considered not only for treatment with quinone based drugs but also nucleoside analogues.   
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Figure 1: Phylogenetic tree showing relationships between azoreductases. 
Those enzymes in red text are from bacteria, those in blue are from mammals and those in green 
from plants. Class 1 enzymes are boxed with a solid line, Class 2 with a dashed line and Class 3 in a 
dotted line. * indicates a characterised azoreductase outside the three defined classes. paYieF, 
paArsH and paMdaB are azoreductases from P. aeruginosa. paWrbA, PA1224, PA1225, and PA4975 
are NAD(P)H quinone oxidoreductases from P. aeruginosa. bsAzoR, efAzoR and rsAzoR are 
azoreductases from Bacillus subtilis, Enterococcus faecalis and Rhodobacter sphaeroides. rNQO1 and 
rNQO2 are rat azoreductases. xaAzoR is a flavin-independent azoreductase from X. azovorans. 
ecMdaB, ecYieF and ecWrbA are NAD(P)H quinone oxidoreductases from E. coli. afNQO, pnNQO, 
tmNQO, pcNQO and atNQO are NAD(P)H quinone oxidoreductases from Archaeoglobus fulgidus, 
Paracoccus denitrificans, Triticum monococcum, Phanerochaete chrysosporium and Arabidopsis 
thaliana respectively. smArsH is an azoreductase from Sinorhizobium meliloti. dgFlav and ecFlav are 
flavodoxins from Desulfovibrio gigas and E. coli respectively. shNQO, reNQO and erNQO are 
uncharacterised proteins from Staphylococcus haemolyticus, Ralstonia eutropha and Erwinia 
chrysanthemi. Adapted from (Ryan et al., 2014). 
Figure 2: the structure of a typical bacterial azoreductase and its mechanism of azoreduction. 
(A) Mechanism for the reduction of an azo drug (olsalazine) by flavin-dependent azoreductases. (B) 
Characteristic homodimeric flavodoxin fold of ecAzoR, a class 1 bacterial azoreductase, (C) detailed 
view of the active site of ecAzoR. In (B) and (C) monomers are coloured blue and gold. The FMN with 
sticks and yellow carbon atoms. In (C) residues surrounding the active site are shown as sticks and 
labelled. (B) and (C) are based upon the structure of ecAzoR PDB 1V4B (Ito et al., 2006) and were 
generated in CCP4MG (McNicholas et al., 2011).  
Fig 3: the binding of azo substrates to azoreductases. 
(A) The structure of balsalazide bound to paAzoR1.  (B) The tautomeric forms of balsalazide that 
occur in solution. (C) The structure of Orange I bound to AzrC from Bacillus sp 29. (D) The structure 
of reactive black 5 bound to Pseudomonas putida azoreductase (ppAzoR). The colouring is as per 
figure 2. The structures are based upon PDBs (A) 3LT5 (Ryan et al., 2010a), (C) 3W79 (Yu et al., 2014) 
and (D) 4C14 (Gonçalves et al., 2013).  
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Figure 4: Proposed mechanism for the reduction of balsalazide by paAzoR1. 
For simplicity only the isoalloxazine ring of FMN and the nicotinamide group of NADPH are shown.  
Figure 5: Reduction of nitro compounds by azoreductases. 
(A) The structure of nitrofurzone bound to paAzoR1, (B) the structure of CB1954 bound to hNQO2. 
(C) Proposed mechanism of nitrofurazone reduction in paAzoR1. In (A) and (B) protein colour coding 
is as in figure 2. For ease of interpretation only one of the two possible binding orientations for 
nitrofurazone is shown in (A) with grey carbon atoms, while water is shown as a green ball. In (B) 
CB1954 is shown with turquoise carbon atoms and the 4’ nitrate is labelled.   These images are 
based upon PDB files (A) 3R6W (Ryan et al., 2011) and (B) 1XI2 (Fu et al., 2005).  
Figure 6: Binding of the chemotherapeutic EO9 to hNQO1 
(A) Overall structure of human hNQO1. (B) Binding of EO9 to hNQO1. (C) Mechanism of hydride 
transfer during reduction of EO9. Protein colour coding is as per figure 2 and in (B) EO9 has turquoise 
carbon atoms. (A) and (B) are based upon PDB file 1GG5 (Faig et al., 2001). 
Sup Fig 1: Structures of compounds mentioned in the review. 
Numbered atoms mentioned in the text are labelled. 
Drug type Drug* Role of NQO1 Tumour type Citation 
Quinone 
β-lapachone Activation 
Breast (Glorieux et al., 2016) 
Lung (Bey et al., 2007) 
Skin (Li et al., 2014) 
Liver  (Li et al., 2014; Park et al., 2014) 
Pancreatic (Ough et al., 2005) 
Doxorubicin Protection  
Bile duct (Zeekpudsa et al., 2014) 
Bladder (Matsui et al., 2010) 
Epirubicin Activation Breast (Fagerholm et al., 2008) 
Streptonigrin Activation 
Colon (Beall et al., 1996) 
Breast (Dehn et al., 2003) 
Pancreatic (Lewis et al., 2005) 
Tanespimycin Activation 
Brain (Gaspar et al., 2009) 
Colon & 
Ovarian 
(Kelland et al., 1999) 
Oesophageal (Hadley et al., 2014) 
Pancreatic (Siegel et al., 2011) 
Nucleoside 
analogues 
Gemcitabine Protection Bile duct 
(Buranrat et al., 2010; Zeekpudsa 
et al., 2014) 
5-fluorouracil Protection 
Bile duct (Zeekpudsa et al., 2014) 
Gastric (Peng et al., 2016) 
Liver (Sutton et al., 2015) 
Table 1: hNQO1 and its association with cancer chemotherapy toxicity.  
*The structures of all drugs are shown in Supplementary Figure 1.  
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Figure 1: Phylogenetic tree showing relationships between azoreductases.  
Those enzymes in red text are from bacteria, those in blue are from mammals and those in green from 
plants. Class 1 enzymes are boxed with a solid line, Class 2 with a dashed line and Class 3 in a dotted line. * 
indicates a characterised azoreductase outside the three defined classes. paYieF, paArsH and paMdaB are 
azoreductases from P. aeruginosa. paWrbA, PA1224, PA1225, and PA4975 are NAD(P)H quinone 
oxidoreductases from P. aeruginosa. bsAzoR, efAzoR and rsAzoR are azoreductases from Bacillus subtilis, 
Enterococcus faecalis and Rhodobacter sphaeroides. rNQO1 and rNQO2 are rat azoreductases. xaAzoR is a 
flavin-independent azoreductase from X. azovorans. ecMdaB, ecYieF and ecWrbA are NAD(P)H quinone 
oxidoreductases from E. coli. afNQO, pnNQO, tmNQO, pcNQO and atNQO are NAD(P)H quinone 
oxidoreductases from Archaeoglobus fulgidus, Paracoccus denitrificans, Triticum monococcum, 
Phanerochaete chrysosporium and Arabidopsis thaliana respectively. smArsH is an azoreductase from 
Sinorhizobium meliloti. dgFlav and ecFlav are flavodoxins from Desulfovibrio gigas and E. coli respectively. 
shNQO, reNQO and erNQO are uncharacterised proteins from Staphylococcus haemolyticus, Ralstonia 
eutropha and Erwinia chrysanthemi. Adapted from (Ryan et al., 2014).  
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Figure 2: the structure of a typical bacterial azoreductase and its mechanism of azoreduction. 
(A) Mechanism for the reduction of an azo drug (olsalazine) by flavin-dependent azoreductases. (B) 
Characteristic homodimeric flavodoxin fold of ecAzoR, a class 1 bacterial azoreductase, (C) detailed view of 
the active site of ecAzoR. In (B) and (C) monomers are coloured blue and gold. The FMN with sticks and 
yellow carbon atoms. In (C) residues surrounding the active site are shown as sticks and labelled. (B) and 
(C) are based upon the structure of ecAzoR PDB 1V4B (Ito et al., 2006) and were generated in CCP4MG 
(McNicholas et al., 2011).  
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Fig 3: the binding of azo substrates to azoreductases.  
(A) The structure of balsalazide bound to paAzoR1.  (B) The tautomeric forms of balsalazide that occur in 
solution. (C) The structure of Orange I bound to AzrC from Bacillus sp 29. (D) The structure of reactive black 
5 bound to ppAzoR. The side chains contributed by each monomer of the azoreductases are coloured a 
different colour, FMN is in yellow sticks. The structures are based upon PDB codes (A) 3LT5 (Ryan et al., 
2010a), (C) 3W79 (Yu et al., 2014) and (D) 4C14 (Gonçalves et al., 2013).  
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Figure 4: Proposed mechanism for the reduction of balsalazide by paAzoR1.  
For simplicity only the isoalloxazine ring of FMN and the nicotinamide group of NADPH are shown.  
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Figure 5: Reduction of nitro compounds by azoreductases.  
(A) The structure of nitrofurzone bound to paAzoR1, (B) the structure of CB1954 bound to hNQO2. (C) 
Proposed mechanism of nitrofurazone reduction in paAzoR1. In (A) and (B) protein colour coding is as in 
figure 2. For ease of interpretation only one of the two possible binding orientations for nitrofurazone is 
shown in (A) with grey carbon atoms, while water is shown as a green ball. In (B) CB1954 is shown with 
turquoise carbon atoms and the 4’ nitrate is labelled.   These images are based upon PDB files (A) 3R6W 
(Ryan et al., 2011) and (B) 1XI2 (Fu et al., 2005).  
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Figure 6: Binding of the chemotherapeutic EO9 to hNQO1  
(A) Overall structure of human hNQO1. (B) Binding of EO9 to hNQO1. (C) Mechanism of hydride transfer 
during reduction of EO9. Protein colour coding is as per figure 2 and in (B) EO9 has turquoise carbon atoms. 
(A) and (B) are based upon PDB file 1GG5 (Faig et al., 2001).  
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